Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEANDOC docetaxel lean body mass pharmacokinetics study
NL-OMON39781Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of docetaxel in breast cancer and metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by Radboud University Medical Center. Started Sep 2012; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
breast cancermetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON39781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39781.